Immix Biopharma Inc (IMMX)

Currency in USD
11.476
+0.136(+1.20%)
Real-time Data·
Earnings results expected in 15 days
IMMX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.06111.860
52 wk Range
1.94012.140
Key Statistics
Prev. Close
11.34
Open
11.12
Day's Range
11.061-11.86
52 wk Range
1.94-12.14
Volume
888.58K
Average Volume (3m)
1.87M
1-Year Change
399.1304%
Book Value / Share
3.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.275
Upside
+76.67%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

Immix Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.275
(+76.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy23.00+100.35%-MaintainAug 14, 2026
Morgan Stanley
Buy19.00+65.51%20.00MaintainAug 11, 2026
H.C. Wainwright
Buy25.00+117.77%20.00MaintainAug 10, 2026
Needham
Buy21.00+82.93%-New CoverageJul 22, 2026
BofA Securities
Buy27.00+135.19%-New CoverageJun 18, 2026

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-0.18 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMMX Income Statement

Compare IMMX to Peers and Sector

Metrics to compare
IMMX
Peers
Sector
Relationship
P/E Ratio
−20.7x−10.5x−0.3x
PEG Ratio
2.880.250.00
Price/Book
3.6x4.4x2.6x
Price / LTM Sales
-115.8x3.1x
Upside (Analyst Target)
76.4%95.8%49.0%
Fair Value Upside
Unlock−7.8%6.3%Unlock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.46M16.02%129.97M
Other Institutional Investors
33.28M46.52%377.38M
Public Companies & Retail Investors
26.80M37.46%303.91M
Total
71.54M100.00%811.26M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Janus Henderson Group Ltd.12.71%9,090,732103,089
Veritas Liberabit Vos, LLC5.47%3,915,91344,406

People Also Watch

18.300
ERAS
+0.11%
29.49
NAVN
+2.66%
25.19
TNGX
-0.40%
2.375
CMPX
+2.81%
41.05
NBTX
-2.38%

FAQ

What Is the Immix Biopharma (IMMX) Stock Price Today?

The Immix Biopharma stock price today is 11.476 USD.

What Stock Exchange Does Immix Biopharma Trade On?

Immix Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immix Biopharma?

The stock symbol for Immix Biopharma is "IMMX."

What Is the Immix Biopharma Market Cap?

As of today, Immix Biopharma market cap is 811.260M USD.

What Is Immix Biopharma's Earnings Per Share (TTM)?

The Immix Biopharma EPS (TTM) is -0.834.

When Is the Next Immix Biopharma Earnings Date?

Immix Biopharma will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is IMMX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immix Biopharma Stock Split?

Immix Biopharma has split 0 times.

What is the current trading status of Immix Biopharma (IMMX)?

As of Aug 18, 2026, Immix Biopharma (IMMX) is trading at a price of 11.476 USD, with a previous close of 11.340 USD. The stock has fluctuated within a day range of 11.061 USD to 11.860 USD, while its 52-week range spans from 1.940 USD to 12.140 USD.

What Is Immix Biopharma (IMMX) Price Target According to Analysts?

The average 12-month price target for Immix Biopharma is 20.275 USD, with a high estimate of 27 USD and a low estimate of 13.2 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +76.67% Upside potential.

What Is the IMMX Premarket Price?

IMMX's last pre-market stock price is 10.670 USD. The pre-market share volume is 1,970.000, and the stock has decreased by -0.670, or -5.910%.

What Is the IMMX After Hours Price?

IMMX's last after hours stock price is 11.341 USD, the stock has decreased by 0.001, or 0.010%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.